FontsA A
ContrastA A
Newsletter Sign-Up

ID-EPTRI

European Paediatric Translational Research Infrastructure

Topic: H2020-INFRADEV-01-2017

Type of Action: RIA

Duration: 24 months

Start date: 1st January 2018

Grant agreement: 777554

Web: (not yet available)

Total request Grant by Consortium: € 3,000,000.-

Total request Grant by BBMRI-ERIC: € 192,500.-

Linked Third Parties/BBMRI-ERIC Framework Agreement: UNIMIB, University of Milano-Bicocca

Benefit/tasks for BBMRI-ERIC: Managing a thematic platform that aims to create ideal conditions for the development and use of paediatric biomarkers, with particular emphasis on enhancing the potential of -omics science in paediatrics.

 

 

Abstract

EPTRI is aimed at harnessing the research and services for the development of medicines for children as well as identifying gaps in paediatric medicines research preventing efficient use of research technologies across pertinent medicine research fields, from discovery and preclinical phase, all the way to ameliorate the therapeutic use of medicines in clinical practice. Sharing understanding of patients’ needs and concerted efforts in critical areas of research will end in further enhancing the health of children and will also have a positive impact on European competitiveness in the pharmaceutical sector.

The new RI (EPTRI) will integrate the critical mass of competencies and structures in the paediatric research sector and the consolidated efforts of scientific groups, Networks of Excellence, Research Consortia, specialty Networks to provide ‘facilities, resources and related services’ to be used by the large scientific community to conduct top-level research in their respective fields of activity. Our final aim is to realise an integrated system which has never been developed in a so structured and comprehensive way in order to bring together all these paediatric activities and the technologies with a big impact on preparing clinical research in so producing a huge acceleration/qualification of procedures for development of new medicines.


This website was co-funded within ADOPT BBMRI-ERIC, a project that has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 676550.
We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we'll assume that you are happy to receive all cookies from this website. If you would like to change your preferences you may do so by following the instructions
Accept